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Pffects of Metformin on Microvascular
unction and Exercise Tolerance in Women
ith Angina and Normal Coronary Arteries
Randomized, Double-Blind, Placebo-Controlled Study
achin Jadhav, MD,† William Ferrell, PHD,† Ian A. Greer, MD,‡
ohn R. Petrie, MD, PHD,§ Stuart M. Cobbe, MD,† Naveed Sattar, MD, PHD*
lasgow and Dundee, Scotland
OBJECTIVES This study sought to determine whether metformin improves vascular function or myocardial
ischemia in nondiabetic subjects.
BACKGROUND Metformin prevents diabetes and may reduce coronary events in patients with diabetes, but
effects on microvascular function and angina are not clear.
METHODS We conducted an 8-week double-blind, randomized, placebo-controlled study of metformin
500 mg twice a day in 33 nondiabetic women with a prior history of normal coronary
angiography but two consecutive positive (ST-segment depression1 mm) exercise tolerance
tests. All parameters were measured at baseline and at 8 weeks, together with an in vivo
assessment of forearm (skin) microvascular function using laser Doppler imaging combined
with iontophoresis.
RESULTS In comparison with placebo (n  17), metformin recipients (n  16) showed significant
reductions in weight and in homeostatic model assessment for insulin resistance (p  0.05,
intention to treat). Endothelium-dependent microvascular responses improved significantly
with metformin (2-way repeated analysis of variance, p 0.0003), but responses with placebo
were unchanged (p  0.50). A comparison of change in acetylcholine responses between
metformin and placebo recipients was significant, whether analyzed by a 2-way analysis of
variance (p  0.0001) or change in area under curves (mean change 392 perfusion units,
95% confidence interval [CI] 20 to 764). Endothelium-independent responses were not
altered. Maximal ST-segment depression (0.84 mm, 95% CI 1.49 to 0.20, p  0.013),
Duke score (6.1 U, 95% CI 1.8 to 10.5, p  0.008), and chest pain incidence (0.11
episodes/day, 95% CI 0.22 to 0.00, p  0.056) improved in metformin relative to placebo
recipients.
CONCLUSIONS Metformin may improve vascular function and decrease myocardial ischemia in nondiabetic
women with chest pain and angiographically normal coronary arteries. Larger controlled trials
of longer duration are warranted. (J Am Coll Cardiol 2006;48:956–63) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.088American College of Cardiology Foundation
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aetformin is an antihyperglycemic agent with a history of
uccessful use in type 2 diabetes. In the UKPDS (United
ingdom Prospective Diabetes Study), metformin was as-
ociated with a 39% lower risk of myocardial infarction
ompared with conventional therapy (1). In a more recent
pidemiologic analysis, metformin was associated with a
ear 40% reduced total and coronary heart disease (CHD)
ortality when compared with sulfonylurea monotherapy
2). In a retrospective analysis of the Prevention of Reste-
osis With Tranilast and Its Outcomes Trial (3), use of
etformin in diabetic patients undergoing coronary inter-
entions decreased adverse clinical events, especially death
nd myocardial infarction (79% risk reduction) when com-
ared with patients treated with either a sulfonylurea or
From the *BHF Glasgow Cardiovascular Research Centre, †Division of Cardio-
ascular and Medical Sciences, and ‡the Division of Developmental Medicine,
niversity of Glasgow, Glasgow Royal Infirmary, Glasgow, Scotland; and the
Division of Medicine and Therapeutics, Ninewells Hospital and Medical School,
undee, Scotland. This study was funded by British Heart Foundation Project Grant,
nd is registered in the U.K. clinical trial registry: ISRCTN: 28863939.m
Manuscript received November 16, 2005; revised manuscript received March 28,
006, accepted April 20, 2006.nsulin. Consistent with such data, metformin variably
mproves lipids and hemostatic function in patients with
ype 2 diabetes (4). One placebo-controlled study in patients
ith type 2 diabetes suggested that metformin may improve
irectly measured vascular function (5) independent of any
eight change, but such studies are lacking in nondiabetic
opulations.
Current therapeutic options for a well-recognized group
f patients with anginal symptoms—a positive exercise
olerance testing (ETT) but angiographically smooth coro-
ary arteries—are limited (6). The condition, sometimes
eferred to as cardiac syndrome X, is not as benign as
riginally reported—patients presenting with unstable an-
ina and nonobstructive atherosclerotic coronary artery
isease have a 2% risk of death or myocardial infarction at
0 days of follow-up (6). It is more common in women in
hom the first presentation of angina occurs either peri-
enopausally or postmenopausally (7). Many such patients
re insulin resistant (8–10) and have associated metabolic
nd hemostatic abnormalities (8,9). Aberrant flow-
ediated coronary vasomotion is pivotal in the pathogenesis
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September 5, 2006:956–63 Metformin in Cardiac Syndrome Xf this syndrome, and occurs as part of a more generalized
systemic) impairment in endothelial function (11). Indeed,
ome centers use systemic assessments of vascular function
n their diagnostic pathways for this group of women (12).
e recently suggested that insulin resistance, acting via
ndothelial dysfunction, may lead to myocardial ischemia
nd that insulin sensitization via metformin or other agents
ay lessen ischemia (13).
In the present study, we tested the hypothesis that
etformin offers dual benefits of improving vascular func-
ion and lessening ischemia in nondiabetic women with
ngina, ischemic ETTs, and normal-appearing coronary
rteries. The primary end point of the study was the effects
f metformin on microvascular function (measured by laser
oppler technology) in women previously categorized after
nvestigation in local hospitals as having cardiac syndrome X
i.e., angina, a positive ETT, and a normal coronary
ngiogram) and who also had a repeat positive ETT before
andomization. The secondary goals of this study were: 1) to
ssess the effects of metformin on chest pain incidence,
aximal ST-segment depression, and Duke score; and 2) to
xamine whether metformin improved other metabolic
arameters linked to insulin resistance in such women.
ETHODS
e recruited 33 women with smooth unobstructed epicar-
ial arteries shown on coronary angiography between 1997
nd 2001 at Glasgow Royal Infirmary. All of these women
ad ongoing typical anginal-type chest pain and had previ-
usly documented 1 mm of flat ST-segment depression
n treadmill exercise testing and a repeat positive ETT at
he pre-randomization visit (i.e., all had 2 consecutive
ositive ETTs). Those with even minor coronary plaque
isease, insignificant up-sloping ST-segment change during
xercise, and coronary artery spasm at angiography were
xcluded. All women underwent pre-trial screening with
lood tests and echocardiography. Other exclusion criteria
ncluded age 70 years, diabetes, uncontrolled hyperten-
ion, valvular or other structural heart disease, and signifi-
ant hepatic or renal impairment.
After approval by the Glasgow Royal Infirmary Ethics
Abbreviations and Acronyms
ACh  acetylcholine
ANOVA  analysis of variance
CHD  coronary heart disease
CI  confidence interval
ETT  exercise tolerance test
HOMA-IR  homeostatic model assessment for insulin
resistance
LDI  laser Doppler imaging
PPAR  peroxisome proliferator-activated receptor
SNP  sodium nitroprusside
tPA  tissue plasminogen activatorommittee, eligible patients gave written informed consent Uo participate. Antianginal therapy was stopped or reduced
or a 4-week period before the trial in the majority of
atients, in keeping with the procedure in a prior trial of
ormonal replacement in cardiac syndrome X in which all
ardiac drugs were stopped 3 weeks before active treatment
r placebo (14). After this period, a chest pain diary was
rovided to each woman, and they were each asked to record
n a daily basis the number of typical anginal-type chest
ains they had suffered. We collated this information
eparately for 4 weeks before treatment and over the 8 weeks
n treatment. All patients were invited to attend in the
asting state for baseline assessments.
aser Doppler imaging (LDI). Microvascular function
as assessed, as detailed previously (15–18), using LDI with
he subject relaxed in the supine position in a quiet,
emperature- and light-controlled environment. This was
arried out before any blood tests were obtained before
andomization and repeated in week 8. Briefly, drugs were
dministered transdermally by iontophoresis, using Perspex
hambers (Moor Instruments Ltd., Axminster, United
ingdom) applied to the extensor forearm surface. The
athodal chamber was filled with sodium nitroprusside
SNP), an endothelium-independent vasodilator (1% dis-
olved in 0.5% sodium chloride), and the anodal chamber with
cetylcholine (ACh), an endothelium-dependent vasodilator
1% dissolved in 0.5% sodium chloride). We also used vehicle
0.5% sodium chloride) controls in the opposite forearm.
ncremental current (expressed as charge, the integral of the
urrent  time relationship, in milliCoulombs) was applied
ith concurrent laser Doppler imaging to record the perfu-
ion response. The perfusion response in flux perfusion units
s presented as both the area under the curve for the scan
nd as a plot of the change in perfusion with drug admin-
stration (in arbitrary perfusion units) against cumulative
harge. The mean (SD) between-day coefficient of varia-
ion in healthy subjects for the ACh response was 6.4%,
hereas the within-day, between-site coefficient of varia-
ion, measured in both forearms, was 8.9%.
lood investigations. Fasting blood samples were col-
ected and stored in aliquots at 80°C for batch analysis at
he end of the study. Tissue plasminogen activator (tPA),
on Willebrand factor (Dako, Copenhagen, Denmark)
ntigens, intercellular adhesion molecule-1 (R&D Systems
nc., Oxon, United Kingdom) and high-sensitivity
-reactive protein (Dako A/S, DK-2600 Glostrup, Den-
ark) were determined by enzyme-linked immunosorbent
ssay techniques. The inter-assay and intra-assay coefficients
f variation were 7% across the range of measured results.
nsulin was measured by a microparticle enzyme immuno-
ssay (Abbott Laboratories, Abbott Park, Illinois) with a
oefficient of variation 8% and sensitivity of 0.8 mU/l.
lasma glucose was measured using the glucose oxidase
ethod (glucose reagent kit, Olympus AU5200, Opticals
K Ltd., London, United Kingdom). Finally, the lipid
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Metformin in Cardiac Syndrome X September 5, 2006:956–63rofile was measured using established methods (Boehr-
nger reagent kits, East Sussex, United Kingdom). Ho-
eostasis model assessment for insulin resistance (HOMA-
R) (fasting plasma insulin [U/ml]  fasting plasma
lucose [mmol/l]/22.5) was used to determine insulin
esistance.
ther clinical measures. Blood pressure was measured in
riplicate following 5 min of rest in the supine position using
n Omron 705-CPII (Optical Healthcare UK Ltd., Milton
eynes, United Kingdom), and the average was taken.
eight and weight measurements were recorded to calculate
ody mass index.
TT. All patients underwent a full Bruce protocol tread-
ill test at baseline and then again after 8 weeks of
etformin or placebo. Exercise time was noted, and maxi-
um ST-segment depression was recorded to the nearest
.5 mm to avoid artefact contamination. The Duke score
calculated as total exercise time in minutes [5maximal
T segment deviation]  [4  index]) was used to provide
n objective measure of treadmill testing performance. A
igure 1. The CONSORT (Consolidated Standards of Reporting Trial) di
ffects. 2There was 1 patient admitted with chest pain, 1 patient with gastroi
olerance test.hest pain index of 0 is assigned if no chest pain is
*
vxperienced, 1 is recorded for nonlimiting pain, and 2 is
ecorded for limiting chest pain. The Duke score has been
hown to indicate prognosis in suspected coronary disease (19).
describing outcomes of all women within the study. 1Gastrointestinal side
nal side effects, and 2 patients with nonspecific symptoms. ETT exercise
able 1. Baseline Characteristics of 33 Women With Repeat
ositive Exercise Tolerance Test at Baseline
Metformin
(n  16)
Placebo*
(n  17)
ge (yrs) 55.8 (8.8) 58.1 (8.4)
ody mass index, kg/m2 28.2 (3.7) 28.1 (3.6)
eight (kg) 71.3 (8.7) 72.7 (9.5)
urrent smoker, n (%) 3 (19) 3 (18)
ostmenopausal, n (%) 10 (63) 8 (47)
ormone replacement therapy use, n (%) 6 (38) 3 (18)
spirin, n (%) 13 (81) 14 (82)
tatin use, n (%) 8 (50) 5 (29)
eta-blockers, n (%) 0 (0) 1 (6)
itrate, n (%) 2 2
alcium channel blockers, n (%) 1 0
icorandil, n (%) 0 2agram
ntestiNo significant difference (p  0.10) in any baseline characteristics in metformin
ersus placebo group.
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September 5, 2006:956–63 Metformin in Cardiac Syndrome Xandomization. Metformin (500-mg tablets) and an iden-
ical placebo were administered in a double-blind random-
zed fashion in a 1:1 ratio. Metformin and placebo were
iven with instructions to take one tablet daily for 1 week,
ncreasing to twice daily for the remaining 7 weeks of the
rial. Randomization was done in blocks of four, with codes
eing held by the pharmacy until data analysis was com-
leted. Compliance was checked by pill counting. Subjects
ere asked to record side effects but to persevere with the
ablets unless symptoms were severe.
tatistical methods. Data are presented as mean (SD) for all
arameters other than chest pain incidence (for which we
resent median and interquartile range). Comparison of
hange in parameter concentrations between groups was ex-
mined by the two-sample t test (or Mann-Whitney U test for
hest pain incidence) and 2-way analysis of variance
igure 2. (A) Baseline and on-treatment (8 weeks) microvascular responses
-way repeated measures analysis of variance [ANOVA]). (B) Baseline a
andomized to placebo (p  0.50, 2-way repeated measures ANOVA).
itroprusside (SNP) in the 16 women randomized to metformin (p  0.46, 2-w
icrovascular responses to SNP in the 17 women randomized to placebo (p ANOVA) between groups (with group and cumulative
harge as main factors) for vascular function measures on an
ntention-to-treat analysis using the last value carried for-
ard in the case of drop-outs. A p value  0.05 was
onsidered significant. Change within groups was examined
y paired t test or Wilcoxon signed rank test (chest pain
ncidence) or 2-way repeated ANOVA for vascular function
baseline vs. treatment and cumulative charge as main
actors). The p values reported for vascular function analyses
efer to the vasodilator response to ACh or SNP at baseline
ompared with the value obtained after treatment with
etformin or placebo (i.e., analysis confined within the
reatment group), or the difference between baseline and
reatment for each vasodilator when comparing metformin
ith placebo. Whether changes in parameters were associ-
ted was assessed using a simple Pearson correlation.
tylcholine (ACh) in the 16 women randomized to metformin (p 0.0003,
-treatment (8 weeks) microvascular responses to ACh in the 17 women
aseline and on-treatment (8 weeks) microvascular responses to sodiumto ace
nd on
(C) Bay repeated measures ANOVA). (D) Baseline and on-treatment (8 weeks)
0.95, 2-way repeated measures ANOVA).
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Metformin in Cardiac Syndrome X September 5, 2006:956–63djustment for change in weight was performed by analysis
f covariance.
ESULTS
eventy-one women were screened for inclusion (Fig. 1).
ifty-six women with a previously documented positive
TT but normal coronary angiograms were seen at a
re-randomization visit. Of these, the 33 who had a repeat
ositive ETT formed the study cohort. Sixteen women were
andomized to receive metformin and 17 were to receive a
lacebo. Statistical analysis was performed as pre-specified
n an intention to treat basis. Compliance, as checked by
ill-counting at the end of the trial, was good with 85% of
tudy completers showing 90% compliance, and compli-
nce was not different between groups (p  0.50). Gastro-
ntestinal side effects were more prevalent in the metformin
roup, affecting 10 of the 16 women, compared with 3 of 17
n the placebo group (chi-square, p  0.05), but were
ransient in the vast majority. No symptoms of hypoglyce-
ia were reported.
emographic characteristics. The baseline characteristics
re given in Table 1. The women randomized to metformin
r placebo were similar for baseline characteristics, including
ge, body mass index, and smoking history.
rimary end point analyses on vascular function. Blood
ow response to ACh improved in women who were
andomized to metformin (2-way repeated measures
NOVA p  0.0003) (Fig. 2A), but there was no signifi-
ant change within placebo recipients (Fig. 2B). Responses
o SNP were unchanged for both the metformin and the
lacebo group (Figs. 2C and 2D). Comparing the change in
Ch response (treatment minus baseline) between met-
ormin and placebo recipients revealed a highly significant
mprovement in the former group relative to the latter
2-way ANOVA p  0.0001), but there was no alteration
or SNP (Figs. 3A and 3B). Comparison of the area under
he curve in metformin relative to placebo recipients was
lso significant (change 392 perfusion units, 95% confi-
ence interval [CI] 20 to 764); p  0.04).
etabolic effects. Analyses of metabolic changes are
hown in Table 2. There was a significant reduction in
eight and HOMA-IR (p  0.026 and p  0.045,
espectively) and a trend toward a reduction in tPA antigen
p  0.09) in metformin relative to placebo recipients.
xercise tolerance data and chest pain frequency. Base-
ine and follow-up data for maximal ST-segment depression
nd chest pain incidence in the women treated with met-
ormin and placebo are shown in Figures 4A and 4B.
aseline values were not significantly different between the
wo groups for either parameter (p  0.23 and p  0.69,
espectively). Significant improvements in both maximal
T-segment depression and chest pain incidence occurred
n the metformin recipients (38% reduction, p  0.007, and
0% reduction, p  0.039, respectively), but such parame-
ers were unaltered in placebo recipients (p  0.45). raximal ST-segment improvement was significantly larger
or metformin than for placebo (p  0.013). Median
eduction in chest pain episodes was larger for metformin
han placebo, and this difference approached significance
0.11 episodes per day, 95% CI 0.22 to 0.00, p 
.056). Duke score improved by a mean of 6.1 U (95% CI
.8 to 10.5, p  0.008) in metformin versus placebo
ecipients. Of the 16 women randomized to active therapy,
3 had a reduction in chest pain incidence, in contrast with
of the 17 in the placebo group (chi-square p  0.01).
ffect of weight change on primary end point, change in
OMA-IR, and ST-segment depression. In the 16
omen randomized to metformin alone, reduction in max-
mal ST-segment depression correlated significantly only to
igure 3. (A) Change over 8 weeks in microvascular responses to acetyl-
holine (ACh) in metformin and placebo groups (p  0.0001, 2-way
epeated measures analysis of variance [ANOVA]). (B) Change over 8
eeks in microvascular responses to sodium nitroprusside (SNP) in
etformin and placebo groups (p  0.55, 2-way repeated measures
NOVA).eduction in tPA antigen concentration (r 0.64, p 0.01)
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September 5, 2006:956–63 Metformin in Cardiac Syndrome Xnd reduction in weight (r  0.55, p  0.024), the former
ssociation independent of the latter. Changes in ACh
esponses and ischemic parameters did not correlate. Im-
ortantly, metformin-induced changes in ACh-mediated
ascular response, HOMA-IR, and to a lesser extent ST-
egment depression were minimally attenuated by adjust-
ent for weight change differences by group (Table 3).
ISCUSSION
his is the first placebo-controlled study to show that
etformin improves endothelium-dependent vascular func-
ion in nondiabetic subjects. Because abnormal systemic/
oronary endothelial function may be causally linked both to
tates of insulin resistance (20,21) and to CHD (22,23), our
ndings are clinically relevant and consistent with other
avorable effects of metformin (1–3) and for its prevention
f type 2 diabetes in subjects at elevated risk (24). Our study
lso suggests that metformin may reduce myocardial ische-
ia in women with exercise-induced angina and normal
oronary arteries. The combined beneficial effects of met-
ormin on vascular function, metabolic parameters, and
schemia suggest its potential to lessen vascular risk. These
ndings are important because the prognosis of this com-
on condition is not as benign as previously considered (6).
We examined effects of skin microvascular function using
DI combined with iontophoresis of vasoactive agents. Our
roup has considerable experience with this technique,
aving shown impaired skin microvascular function in
besity, in diabetes, and in the post-prandial state, whereas
thers have linked it to insulin resistance (15–18). The
etformin-treated subjects showed a clear improvement in
Ch response (Figs. 2A and 3A), a finding also consistent
n analyses of completers (data not shown).
Why should vascular function improve with metformin?
f insulin resistance is a precursor to endothelial dysfunc-
ion, ameliorating insulin resistance should improve it.
able 2. Clinical Characteristics of the Metformin and Placebo G
etabolic Parameters
Metformin (n  16
Baseline Chang
eight (kg) 71.3 (8.7) 0.64 (1
asting glucose (mmol/l) 4.89 (0.5) 0.07 (0
OMA-IR 1.80 (1.02) 0.51 (0
ystolic blood pressure (mm Hg) 130.0 (21.0) 5.7 (2
iastolic blood pressure (mm Hg) 78.3 (8.7) 2.4 (8
otal cholesterol (mmol/l) 4.74 (0.7) 0.04 (0
riglycerides (mmol/l) 1.31 (0.5) 0.08 (0
ow-density lipoprotein cholesterol (mmol/l) 2.85 (0.5) 0.06 (0
igh-density lipoprotein cholesterol (mmol/l) 1.49 (0.3) 0.041 (0
issue plasminogen activator (ng/ml) 7.00 (3.2) 1.28 (1
on Willebrand factor (IU/dl) 122 (41) 7 (1
ntercellular adhesion molecule-1 (ng/ml) 273 (75) 7 (4
-reactive protein (mg/l) 3.45 (2.0) 0.10 (1
ata are mean (SD).
HOMA-IR  homeostatic model assessment for insulin resistance.etformin induced a small but significant reduction in (eight (approximately 1 kg or 2% relative to placebo) and a
ignificant change in HOMA-IR relative to placebo
20%). Although this reduction in HOMA-IR was
lightly attenuated (p  0.045 to p  0.08) after adjusting
or weight change, neither change correlated with improve-
ent in ACh response. However, reduction in tPA antigen
partially endothelial-derived) concentration in the met-
ormin group did correlate with reduction in maximal
T-segment depression; of note, elevated tPA is an inde-
endent predictor of both CHD events (25) and type 2
iabetes (26). Of interest, improvements in vascular func-
ion occurred despite no significant changes in glucose or
nflammation parameters. De Jager et al. (27) reported that
eneficial effects of metformin on circulating markers of
ndothelial function were independent of glycemic changes
n patients with type 2 diabetes. Changes in vascular
unction were also not explained by change in weight (Table
). It should be noted that metformin has other complex
ntra-cellular actions, one of which is activation of AMP-
ctivated protein kinase (28,29), and to exert this action by
hosphorylation of the endothelial isoform of endothelial
itric oxide synthase at serine 177 in human aortic endo-
helial cells (30,31). This is a plausible candidate mechanism
or the vasoactive effects of metformin, independent of its
ffects on insulin action, weight, or other parameters.
Our study was designed to detect change in endothelial
unction, but we were also interested in effects on ischemia
iven prior, albeit uncontrolled, evidence of such benefits
ith metformin and troglitazone in patients with diabetes
nd angina (reviewed in [13]). Our positive results on the
ffects of metformin (but not placebo) on maximal ST-
egment depression, Duke score, and episodes of chest pain
uggest a reduction in ischemia. As such, our findings are of
otential clinical importance and are in keeping with recent
ovel approaches to target metabolic processes in the
asculature as a method of reducing myocardial ischemia
s at Baseline and Comparison of Change Over 8 Weeks in
Placebo (n  17)
Mean Difference,
95% Confidence Interval p ValueBaseline Change
72.7 (9.5) 0.48 (1.29) 1.13 (2.10, 0.15) 0.026
4.87 (0.4) 0.11 (0.28) 0.18 (0.46, 0.10) 0.20
1.92 (1.32) 0.01 (0.62) 0.52 (0.014, 1.025) 0.045
136.5 (11.2) 0.12 (8.7) 5.8 (8.2, 19.8) 0.40
81.3 (26.0) 3.6 (6.6) 1.2 (4.4, 6.8) 0.66
5.27 (0.9) 0.21 (0.68) 0.17 (0.33, 0.67) 0.49
1.40 (0.7) 0.05 (0.36) 0.13 (0.40, 0.14) 0.33
3.26 (0.8) 0.13 (0.50) 0.07 (0.29, 0.43) 0.70
1.30 (0.4) 0.015 (0.11) 0.06 (0.04, 0.15) 0.23
8.53 (3.2) 0.06 (2.5) 1.3 (2.9, 0.23) 0.09
134 (36) 8 (16) 1.0 (12, 10) 0.86
264 (68) 5 (12) 2.3 (24, 20) 0.83
3.3 (2.9) 0.31 (0.67) 0.4 (1.5, 0.6) 0.42roup
)
e
.45)
.47)
.79)
6.0)
.9)
.71)
.39)
.53)
.15)
.93)
4)
0)
.8)32). Similarly, in studies of diabetes patients, thiazo-
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Metformin in Cardiac Syndrome X September 5, 2006:956–63idinedione insulin sensitizers have been shown to lessen
nginal pain (33), improve myocardial blood flow (34), and
egulate activity of endothelial nitric oxide synthase, the
atter occurring at least in part via a peroxisome proliferator-
ctivated receptor (PPAR)-gamma action (35). Interest-
ngly, a significantly lower incidence of admission for angina
as reported for the pioglitazone arm relative to placebo in
he recent PRO-ACTIVE (Prospective Pioglitazone Clin-
cal Trial in Macrovascular Events) study (36).
tudy limitations. We acknowledge that a more robust
easure of myocardial ischemia would have enhanced the
tudy. Nevertheless, the women in our cohort had a good
istory of exercise angina, two consecutive positive ETTs,
nd evidence of impaired systemic vascular dysfunction, a
ollection of findings that, we believe, would be considered
atisfactory by many cardiologists to make the diagnosis of
igure 4. (A) Mean maximal ST-segment depression during exercise
olerance test (ETT) (mm) at baseline and on treatment (8 weeks) in the
3 women randomized to placebo (n  17) or metformin (n  16). (B)
edian chest pain incidence before randomization and on treatment in the
3 women randomized to placebo (n  17) or metformin (n  16).ardiac syndrome X. Moreover, the consistency of improve-ents in vascular, metabolic, and ischemia data by chest
ain questionnaire and during the ETT in the metformin
roup, even at a relatively low dose, is reassuring. We also
ccept that although the measure of vascular function we
sed is well validated, it would have been optimal to
easure endothelial function in coronary arteries directly.
hat noted, to repeat coronary angiography in a group with
ecently documented normal coronary arteriography would
ave raised ethical issues.
onclusions. In summary, using a double-blind placebo-
ontrolled study design, we have shown that metformin
mproves endothelium-dependent vascular function and
schemia in women with a history of exercise-induced
ngina, reproducible positive ETTs, but normal coronary
rteries on angiography. Such effects suggest that metformin
ay have the potential not only to improve clinical symp-
oms in this patient group, possibly via positive effects on
icrovascular function, but also to reduce vascular risk in
he longer term. Larger studies are now required to expand
hese novel findings.
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